Incidence and Management of Elevated Intraocular Pressure After Silicone Oil Injection

Al-Jazzaf, Adel M; Netland, Peter A.; Charles, Steve

doi:10.1097/01.ijg.0000145811.62095.fa

Cited by 114 publications

(94 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One patient was uncontrolled with topical therapy and required surgical intervention. This rate is consistent with previously reported rates utilizing silicone oil 15,16…”

Section: Discussionsupporting

confidence: 93%

Densiron® 68 as an intraocular tamponade for complex inferior retinal detachments

Hussain¹,

Banerjee²

2011

OPTH

View full text Add to dashboard Cite

Introduction:Densiron® 68 is a high-density liquid used to tamponade inferior retinal detachments. We present a case series of 12 patients treated with Densiron as an intraocular tamponade agent.Methods:A retrospective analysis of 12 eyes in 12 patients was carried out. The primary endpoint was anatomic reattachment of the retina following removal of Densiron oil.Results:All patients had inferior detachments; 33% had associated proliferative vitreoretinopathy (PVR). Densiron was utilized as a primary agent in five patients (42%); the remaining patients had prior unsuccessful surgery for retinal reattachment, including pars plana vitrectomy, cryotherapy, laser, encirclement, gas (C3F8 or C2F6), or silicone oil. Eleven patients (91%) had successful reattachment of the retina at 3 months following removal of Densiron; one patient had extensive PVR, total retinal detachment, preretinal macula fibrosis, and chronic hypotony, and surgical intervention was unsuccessful. Six patients (50%) had raised intraocular pressure (IOP), resolving in the majority of cases following Densiron removal; two patients had long-term raised IOP requiring topical or surgical therapy. Of the six phakic patients, 50% developed significant cataract in the operated eye. Of those with successful retinal reattachment, visual outcome was variable, with 36% patients gaining two to four lines on Snellen, 27% remaining objectively the same, and 36% losing one to two lines.Conclusion:The anatomic success rate is high (91%) in patients requiring Densiron tamponade for inferior retinal detachments with or without evidence of PVR either as a primary or secondary intervention. A common complication is raised IOP; however, this most often resolves following removal of the oil.

show abstract

“…One patient was uncontrolled with topical therapy and required surgical intervention. This rate is consistent with previously reported rates utilizing silicone oil 15,16…”

Section: Discussionsupporting

confidence: 93%

Densiron® 68 as an intraocular tamponade for complex inferior retinal detachments

Hussain¹,

Banerjee²

2011

OPTH

View full text Add to dashboard Cite

show abstract

“…The true incidence of glaucoma after silicone oil injection is difficult to ascertain. The rates of elevated IOP or glaucoma range from 2.2% at 6 months to 56% at 8 months [56–75], with more recent studies reporting lower rates, likely as a result of improvements in surgical techniques and materials. Higher viscosity silicone oil (5000 centistokes) has been noted to result in fewer emulsified silicone droplets in the anterior chamber and a lower risk of glaucoma [76].…”

Section: Glaucoma After Silicone Oil Injectionmentioning

confidence: 99%

“…Aqueous suppressants are used to reduce IOP. In a study by Al-Jazzaf et al [75], 78% of patients (40 of 51) with glaucoma after PPV and silicone oil injection were treated successfully with medications alone. The IOP was controlled in most eyes with topical beta-blockers and prostaglandin analogues.…”

Section: Glaucoma After Silicone Oil Injectionmentioning

confidence: 99%

Glaucoma management after vitreoretinal surgeries

Kornmann

Gedde

2016

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

Purpose of review The surgical management of retinal disorders, including scleral buckling procedures, pars plana vitrectomy, and intravitreal injections of gas or silicone oil, can lead to short-term elevations in intraocular pressure (IOP) and ultimately long-term glaucomatous damage if not treated in a timely manner. Glaucoma in these cases is commonly refractory to conventional therapies. This review highlights the treatment strategies for glaucoma in eyes that have previously undergone vitreoretinal surgery. Recent findings Although medical therapy is often used initially to control a temporary rise in IOP, laser and surgical therapy may be required to treat sustained IOP elevation and subsequent glaucomatous damage in eyes that have undergone intraocular surgery for retinal disorders. Glaucoma drainage devices are an important treatment modality, particularly when there is high risk of failure with filtering surgery. Summary Previous vitreoretinal surgery is a known risk factor for the development of glaucoma. Treatment is usually initiated with medical therapy, however, surgical intervention is frequently required to control IOP and prevent progressive glaucomatous damage in patients with refractory glaucoma.

show abstract

“…Long-term glaucoma following SSO use is uncommon in current surgery, but past studies have indicated an incidence ranging from 3% to 40% of cases 4,10,14,15. Some of these cases can develop secondary glaucoma 5,14–16.…”

Section: Introductionmentioning

confidence: 99%

Intraocular pressure changes following the use of silicone oil or Densiron® 68 as endotamponade in pars plana vitrectomy

Romano¹,

Angi²,

Romano³

et al. 2010

OPTH

View full text Add to dashboard Cite

ObjectiveTo compare the effects of standard silicone oil 5700 (SSO) and heavy silicone oil (HSO) such as Densiron® 68 on intraocular pressure (IOP).Materials and methodsRetrospective case series including 180 eyes (105 treated with SSO and 75 with HSO). IOP was measured before surgery, 1 day after, and then at 1-, 3-, 6-, and 12-month follow-ups.ResultsIn the SSO group, a significant increase in IOP occurred in 14% of the eyes (15/105) at 1 day postoperatively, and persisted in 11.4% (12/105) at 1-month follow-up. In the HSO group, a persistent elevated IOP was recorded in 20% of the eyes (15/75) at 1 day postoperatively, and in 16% (12/75) at 1-month follow-up. At 12-month follow-up, mean IOP was 16.7 ± 8.7 mmHg and 19.7 ± 3.8 mmHg, respectively, in the SSO and HSO groups. The difference between the 2 groups was always not significant.ConclusionOverall, the use of Densiron 68 was not associated with higher IOP values as compared with SSO.

show abstract

Incidence and Management of Elevated Intraocular Pressure After Silicone Oil Injection

Cited by 114 publications

References 34 publications

Densiron® 68 as an intraocular tamponade for complex inferior retinal detachments

Densiron® 68 as an intraocular tamponade for complex inferior retinal detachments

Glaucoma management after vitreoretinal surgeries

Intraocular pressure changes following the use of silicone oil or Densiron® 68 as endotamponade in pars plana vitrectomy

Contact Info

Product

Resources

About

Incidence and Management of Elevated Intraocular Pressure After Silicone Oil Injection

Cited by 114 publications

References 34 publications

Densiron&reg; 68 as an intraocular tamponade for complex inferior retinal detachments

Densiron&reg; 68 as an intraocular tamponade for complex inferior retinal detachments

Glaucoma management after vitreoretinal surgeries

Intraocular pressure changes following the use of silicone oil or Densiron&reg; 68 as endotamponade in pars plana vitrectomy

Contact Info

Product

Resources

About

Densiron® 68 as an intraocular tamponade for complex inferior retinal detachments

Densiron® 68 as an intraocular tamponade for complex inferior retinal detachments

Intraocular pressure changes following the use of silicone oil or Densiron® 68 as endotamponade in pars plana vitrectomy